204 related articles for article (PubMed ID: 12042705)
1. Ras processing as a therapeutic target in hematologic malignancies.
Le DT; Shannon KM
Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Reuter CW; Morgan MA; Bergmann L
Blood; 2000 Sep; 96(5):1655-69. PubMed ID: 10961860
[TBL] [Abstract][Full Text] [Related]
3. Ras family signaling: therapeutic targeting.
Cox AD; Der CJ
Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Lancet JE; Karp JE
Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
[TBL] [Abstract][Full Text] [Related]
5. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
6. Farnesyl transferase inhibitors in myeloid malignancies.
Lancet JE; Karp JE
Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Karp JE; Lancet JE
Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors.
Sebti SM; Adjei AA
Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
[TBL] [Abstract][Full Text] [Related]
11. Current status of clinical trials of farnesyltransferase inhibitors.
Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
[TBL] [Abstract][Full Text] [Related]
12. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
13. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Kantarjian HM; Cortes JE; Rowe JM; Kurzrock R
Semin Hematol; 2002 Jul; 39(3 Suppl 2):36-8. PubMed ID: 12214292
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the ras oncogene as therapeutic targets.
Ghobrial IM; Adjei AA
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
16. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
17. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
Adjei AA
Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
Morgan MA; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
[TBL] [Abstract][Full Text] [Related]
20. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
